Silexion Therapeutics (SLXN) stock saw a massive rally on Thursday following the release of new pre-clinical data from the clinical-stage biotechnology company. This pre-clinical trial was focused on the biodistribution and therapeutic activity of SIL204 following subcutaneous administration. The drug reached all primary sites of pancreatic cancer metastasis and also showed anti-tumor activity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion Therapeutics, said, “Demonstrating drug distribution to the liver, peritoneum, and lung, which represent the primary sites of metastatic pancreatic cancer spread, supports our approach of combining intratumoral delivery for primary tumors with systemic administration for disseminated disease.”
Silexion Therapeutics noted that it’s on track to start Phase 2/3 clinical trials of SIL204 in the first half of 2026. The company intends to complete regulatory submissions for these trials in Q4 2025 and Q1 2026.
Silexion Therapeutics Stock Movement Today
Silexion Therapeutics stock was up 188.07% in pre-market trading on Thursday, following an 11.36% fall yesterday. Investors will note the shares have also decreased 85.12% year-to-date and 96.98% over the past 12 months.
Today’s news brought heavy trading to SLXN stock, as more than 6 million shares changed hands. That’s already well above the company’s three-month daily average trading volume of about 166,000 shares.
Is Silexion Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Silexion Therapeutics is Moderate Buy, based on a single Buy rating over the past three months. With that comes a $24 SLXN stock price target, representing a potential 436.12% upside for the shares.
